GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
I'm PortAI, I can summarize articles.
GSK has announced a $2.2 billion acquisition of RAPT Therapeutics, targeting a new food allergy drug, ozureprubart, which requires administration once every three months. The deal's effective cost is $1.9 billion after accounting for RAPT's cash reserves. RAPT's shares surged 64% in premarket trading, while GSK's shares fell 1% in London. The new drug aims to provide an alternative for patients who are ineligible for existing therapies, which require more frequent injections.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments